Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04750616 · ClinicalTrials.gov registry record · Phase 2

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

A Phase 2 study of Acute Kidney Injury and Ischemia Reperfusion Injury, sponsored by Kaiser Permanente.

Recruiting
Registry status
Phase 2
Development phase
304
Enrollment target
1
Study location

NCT04750616 is a Phase 2 study of Acute Kidney Injury and Ischemia Reperfusion Injury that is actively recruiting participants, run by Kaiser Permanente. The registered enrollment target is 304 participants, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04750616, a Phase 2 study of Acute Kidney Injury and Ischemia Reperfusion Injury, is actively recruiting participants, sponsored by Kaiser Permanente.

RECRUITING
Registry status
Phase 2
Development phase
304 participants
Enrollment target
1
Study location

Study Summary

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

Interventions

  • DRUG Placebo
  • DRUG Niacinamide

Study Locations (1)

California

  • Kaiser Permanente San Francisco Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 304 participants
Start Date 2021-09-13
Est. Completion 2025-06-30
Phase Phase 2

Sponsor

Kaiser Permanente

294 total trials

What the Registry Record Tells You About NCT04750616

The ClinicalTrials.gov registry entry for NCT04750616 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (87% lower). The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04750616 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04750616 about?

NCT04750616 is a clinical study titled "NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial". A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

What is the current status of trial NCT04750616?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2021-09-13. Estimated completion is 2025-06-30.

What conditions does trial NCT04750616 study?

This clinical trial studies the following conditions: Acute Kidney Injury, Ischemia Reperfusion Injury, Myocardial Injury.

What interventions are being tested in trial NCT04750616?

The interventions under investigation include: Placebo (DRUG), Niacinamide (DRUG).

Who is sponsoring clinical trial NCT04750616?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04750616 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Kidney Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.